High-speed imaging reveals neurophysiological links to behavior in an animal model of depression

Science

Volumn 317, Issue 5839, 2007, Pages 819-823

  Airan, Raag D ^a   Meltzer, Leslie A ^b   Roy, Madhuri ^a   Gong, Yuqing ^a,b   Chen, Han ^a   Deisseroth, Karl ^a,b  

^a Stanford University ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; HALOPERIDOL; IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIORAL RESPONSE; BRAIN; DYE; IMAGING METHOD; MODEL; RODENT; SYMPTOM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC STRESS; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; DIAGNOSTIC IMAGING; DISEASE MODEL; HIPPOCAMPUS; IMAGING SYSTEM; MOOD DISORDER; NEUROPHYSIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STIMULUS RESPONSE; SYMPTOMATOLOGY; VOLTAGE SENSITIVE DYE IMAGING SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BEHAVIOR, ANIMAL; DENTATE GYRUS; DEPRESSIVE DISORDER; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; FEMALE; FLUOXETINE; HIPPOCAMPUS; IMIPRAMINE; MOTOR ACTIVITY; NERVE NET; NEURONS; RATS; RATS, INBRED F344; SEROTONIN UPTAKE INHIBITORS; STRESS;

ANIMALIA; RATTUS;

EID: 34547125241     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1144400     Document Type: Article

References (28)

1. S. Campbell, G. Macqueen, J. Psychiatry Neurosci. 29, 417 (2004).
2. H. S. Mayberg et al., Biol. Psychiatry 48, 830 (2000).
3. D. A. Seminowicz et al., Neuroimage 22, 409 (2004).
4. J. L. Warner-Schmidt, R. S. Duman, Hippocampus 16, 239 (2006).
5. L. Santarelli et al., Science 301, 805 (2003).
6. C. Mirescu, E. Gould, Hippocampus 16, 233 (2006).
7. R. M. Sapolsky, Arch. Gen. Psychiatry 57, 925 (2000).
8. L. H. Tecott, E. J. Nestler, Nat. Neurosci. 7, 462 (2004).
9. W. M. Cowan, D. H. Harter, E. R. Kandel, Annu. Rev. Neurosci. 23, 343 (2000).
10. J. F. Cryan, A. Holmes, Nat. Rev. Drug Discov. 4, 775 (2005).
11. A. Grinvald, R. Hildesheim, Nat. Rev. Neurosci. 5, 874 (2004).
12. P. Willner, Neuropsychobiology 52, 90 (2005).
13. See supporting material on Science Online.
14. D. M. Bannerman et al., Neurosci. Biobehav. Rev. 28, 273 (2004).
15. J. F. Cryan, R. J. Valentino, I. Lucki, Neurosci. Biobehav. Rev. 29, 547 (2005).
16. C. López-Rubalcalva, I. Lucki, Neuropsychopharmacology 22, 191 (2000).
17. S. G. Walling, C. W. Harley, J. Neurosci. 24, 598 (2004).
18. S. Birnstiel, T. J. List, S. G. Beck, Synapse 20, 117 (1995).
19. J. E. Lisman, A. A. Grace, Neuron 46, 703 (2005).
20. M. E. Hasselmo, H. Eichenbaum, Neural Netw. 18, 1172 (2005).
21. H. S. Mayberg et al., Am. J. Psychiatry 156, 675 (1999).
22. F. A. Henn, B. Vollmayr, Biol. Psychiatry 56, 146 (2004).
23. H. A. Cameron, R. D. G. McKay, J. Comp. Neurol. 435, 406 (2001).
24. B. S. McEwen, Annu. Rev. Neurosci. 22, 105 (1999).
25. H. S. Mayberg et al., Neuron 45, 651 (2005).
26. E. J. Nestler et al., Neuron 34, 13 (2002).
27. W. C. Drevets, Curr. Opin. Neurobiol. 11, 240 (2001).
28. We thank the Deisseroth lab, J. R. Huguenard, T. D. Palmer, R. C. Malenka, and B. K. Ormerod for helpful discussions. Supported by the National Institute on Drug Abuse, the National Institute of Mental Health, the NIH Director's Pioneer Award, NARSAD, the American Psychiatric Institute for Research and Education, and the Snyder, Culpeper, Coulter, Klingenstein, Whitehall, McKnight, and Albert Yu and Mary Bechmann Foundations (K.D.); the Stanford Medical Scientist Training Program (R.D.A.); and a Stanford Bio-X predoctoral fellowship (L.A.M.).